In situ fluorescence monitoring of diagnosis and treatment: a versatile nanoprobe combining tumor targeting based on MUC1 and controllable DOX release by telomerase

Chem Commun (Camb). 2018 Jul 19;54(59):8277-8280. doi: 10.1039/c8cc05052j.

Abstract

We have constructed versatile drug-loaded nanoprobes capable of responding to both MUC1 and telomerase and achieving intracellular drug release. Besides, the synthesized drug-loaded nanoprobes can realize the in situ imaging observation of the whole process of nanoprobes targeting the tumor cell membrane, the transmembrane entering the cytoplasm and the release of DOX into the cell nucleus.

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Aptamers, Nucleotide / chemical synthesis
  • Aptamers, Nucleotide / chemistry
  • Aptamers, Nucleotide / metabolism
  • DNA Probes / chemical synthesis
  • DNA Probes / chemistry
  • DNA Probes / metabolism*
  • Doxorubicin / pharmacology*
  • Drug Carriers / chemical synthesis
  • Drug Carriers / chemistry
  • Drug Carriers / metabolism
  • Drug Liberation
  • Fluorescence
  • Fluorescent Dyes / chemistry
  • Gold / chemistry
  • HeLa Cells
  • Humans
  • Metal Nanoparticles / chemistry*
  • Mucin-1 / metabolism*
  • Particle Size
  • Telomerase / metabolism*

Substances

  • Antineoplastic Agents
  • Aptamers, Nucleotide
  • DNA Probes
  • Drug Carriers
  • Fluorescent Dyes
  • MUC1 protein, human
  • Mucin-1
  • Gold
  • Doxorubicin
  • Telomerase